)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bio-Techne
Bio-Techne (TECH) investor relations material
Bio-Techne Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary6 Nov, 2026
Executive summary
Q1 FY27 net sales rose 5% YoY to $299.7M; organic revenue increased 7%, with held-for-sale businesses reducing growth by 2% and FX impact immaterial.
Shareholders approved the proposed Merck KGaA acquisition on Sept. 23; closing is expected by late 2026 or early 2027, subject to customary conditions.
Financial highlights
Net earnings were $28.3M vs. $38.2M YoY; operating income was $36.6M vs. $47.7M, while revenue was $299.7M vs. $286.6M.
Adjusted net earnings were $70.1M vs. $66.0M YoY; adjusted diluted EPS was $0.44 vs. $0.42.
Operating cash flow was $73.1M vs. $27.6M YoY, primarily reflecting timing of payments on operating assets and liabilities.
Royalty revenue was $14.5M vs. $5.6M YoY; consumables revenue was $237.3M vs. $231.6M, instruments $25.5M vs. $21.8M, and services $22.5M vs. $27.5M.
Outlook and guidance
FY27 remaining capital expenditures are expected to be ~$28M, focused on capacity expansion to support expected sales growth.
Excluding discrete items, the expected consolidated income tax rate for the remainder of FY27 is 23%–27%.
Management expects available cash, operating cash generation, and remaining credit to cover operating needs, facility expansion, capital additions, and dividends for at least the next 12 months.
Merger closing is expected by late 2026 or early 2027, contingent on customary closing conditions, including regulatory approvals.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bio-Techne
- Shareholders will vote on a merger with Merck KGaA amid litigation and enhanced proxy disclosures.TECH
Proxy filing - Shareholders to receive $73.00 per share in cash as part of the planned merger closing by early 2027.TECHProxy filing
- Shareholders will vote on the Merck KGaA acquisition, with closing expected by early 2027.TECHProxy filing
- Acquisition gains regulatory approval; shareholder vote and key risks remain.TECHProxy filing
- Shareholders will vote on a $73/share cash acquisition, with board support and detailed executive payouts.TECHProxy filing
- Q4 organic revenue up 3%, GAAP EPS at $0.35, and acquisition by Merck KGaA announced.TECHQ4 2026
- Shareholders will vote on a $73.00 per share cash acquisition, with board unanimous support.TECHProxy filing
- Shareholders to receive $73.00 per share in cash upon merger closing, expected by early 2027.TECHProxy filing
- Strong innovation and market recovery position the business for accelerated growth by late 2026.TECH53rd Annual Nasdaq Investor Conference
Next Bio-Techne earnings date
Q2 20273 Feb, 2027
Bio-Techne
Next Bio-Techne earnings date
Q2 20273 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bio-Techne Corporation develops, manufactures, and sells life sciences research and clinical diagnostic products. The company’s portfolio includes proteins, antibodies, reagents, and diagnostic instruments supporting academic research, biopharmaceutical production, and clinical testing. Bio-Techne serves scientists and healthcare providers globally. The company is headquartered in Minneapolis, Minnesota, and its shares are listed on the NASDAQ.